Horizon Pharma (HZNP) PT Bumped to $30 at BMO Capital Amid 'Very Solid' Q2
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
BMO Capital analyst Gary Nachman reiterated an Outperform rating and bumped his price target on Horizon Pharma (NASDAQ: HZNP) to $30.00 (from $29.00) following "very solid" 2Q with revenue of $257mn vs. BMO/consensus of $235mn/235mn. EPS was $0.62 vs. BMO/consensus of $0.50/0.50 using the old tax methodology ($0.56 using a modified methodology.
Nachman commented, "The top and bottom line beats were high quality in our view, with almost all key products generating upside, while gross margin was stronger and the company spent more and still generated nice upside to EPS. HZNP reiterated its guidance for FY16, and investors should now have more confidence those targets will be achieved."
Shares of Horizon Pharma closed at $20.10 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- T-Mobile (TMUS) PT, Estimates Raised at Jefferies
- Netflix (NFLX) PT Raised to $140 at Guggenheim
- Itron (ITRI): Raising PT Ahead Of Earnings - Baird
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change
Related EntitiesBMO Capital
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!